The Efficacy and Safety of Milnacipran for Treatment of Fibromyalgia. A Randomized, Double-blind, Placebo-controlled Trial

REFERENCES

1. 1.↵
   1. Hudson JI,
   2. Pope HG, Jr

   . The relationship between fibromyalgia and major depressive disorder. Rheum Dis Clin North Am 1996;22:285–303.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Wolfe F,
   2. Smythe HA,
   3. Yunus MB,
   4. et al

   . The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160–72.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Mease P

   . Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol 2005;32 Suppl 756–21.

   OpenUrlFREE Full Text
4. 4.↵
   1. Baker K,
   2. Barkhuizen A

   . Pharmacologic treatment of fibromyalgia. Curr Pain Headache Rep 2005;9:301–6.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Wolfe F,
   2. Ross K,
   3. Anderson J,
   4. Russell IJ,
   5. Hebert L

   . The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19–28.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Clauw DJ,
   2. Chrousos GP

   . Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation 1997;4:134–53.

   OpenUrlPubMed
7. 7.
   1. Yunus MB

   . Towards a model of pathophysiology of fibromyalgia: aberrant central pain mechanisms with peripheral modulation. J Rheumatol 1992;19:846–50.

   OpenUrlPubMed
8. 8.↵
   1. Bradley LA,
   2. McKendree-Smith NL,
   3. Alberts KR,
   4. Alarcon GS,
   5. Mountz JM,
   6. Deutsch G

   . Use of neuroimaging to understand abnormal pain sensitivity in fibromyalgia. Curr Rheumatol Rep 2000;2:141–8.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Goldenberg DL,
   2. Burckhardt C,
   3. Crofford L

   . Management of fibromyalgia syndrome. JAMA 2004;292:2388–95.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Chu LF,
    2. Clark DJ,
    3. Angst MS

    . Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain 2006;7:43–8.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Gendreau RM,
    2. Thorn MD,
    3. Gendreau JF,
    4. et al

    . Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005;32:1975–85.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Clauw DJ,
    2. Mease P,
    3. Palmer RH,
    4. Gendreau RM,
    5. Wang Y

    . Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008;30:1988–2004.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Branco JC,
    2. Perrot S,
    3. Bragee G,
    4. Zacchrisson O,
    5. Mikkelsen K,
    6. Mainguy Y

    . Milnacipran for the treatment of fibromyalgia syndrome: a European multicenter, randomized, double-blind, placebo-controlled trial [abstract]. Ann Rheum Dis 2008;67 Suppl II:251.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Vaishnavi SN,
    2. Nemeroff CB,
    3. Plott SJ,
    4. Rao SG,
    5. Kranzler J,
    6. Owens MJ

    . Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 2004;55:320–2.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Dubner R,
    2. Hargreaves KM

    . The neurobiology of pain and its modulation. Clin J Pain 1989;5 Suppl 2S1–4.

    OpenUrlCrossRef
16. 16.↵
    1. Jones CK,
    2. Eastwood BJ,
    3. Need AB,
    4. Shannon HE

    . Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: evidence for synergism between serotonergic and noradrenergic reuptake inhibition. Neuropharmacology 2006;51:1172–80.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Mochizucki D

    . Serotonin and noradrenaline reuptake inhibitors in animal models of pain. Hum Psychopharmacol 2004;19 Suppl 1S15–9.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Russell IJ,
    2. Vaeroy H,
    3. Javors M,
    4. Nyberg F

    . Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992;35:550–6.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Stahl SM

    . The psychopharmacology of energy and fatigue. J Clin Psychiatry 2002;63:7–8.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Stahl SM

    . Neurotransmission of cognition, part 1, Dopamine is a hitchhiker in frontal cortex: norepinephrine transporters regulate dopamine. J Clin Psychiatry 2003;64:4–5.

    OpenUrlPubMed
21. 21.↵
    1. Moret C,
    2. Charveron M,
    3. Finberg JP,
    4. Couzinier JP,
    5. Briley M

    . Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 1985;24:1211–9.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Max MB,
    2. Lynch SA,
    3. Muir J,
    4. Shoaf SE,
    5. Smoller B,
    6. Dubner R

    . Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250–6.

    OpenUrlPubMed
23. 23.
    1. Atkinson JH,
    2. Slater MA,
    3. Capparelli EV,
    4. et al

    . Efficacy of noradrenergic and serotonergic antidepressants in chronic back pain: a preliminary concentration-controlled trial. J Clin Psychopharmacol 2007;27:135–42.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Atkinson JH,
    2. Slater MA,
    3. Wahlgren DR,
    4. et al

    . Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity. Pain 1999;83:137–45.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Lecrubier Y

    . Milnacipran: the clinical properties of a selective serotonin and noradrenaline reuptake inhibitor. Hum Psychopharmacol 1997;12:S127–S34.

    OpenUrl
26. 26.↵
    1. Puozzo C,
    2. Lens S,
    3. Reh C,
    4. et al

    . Lack of interaction of milnacipran with the cytochrome P450 isoenzymes frequently involved in the metabolism of antidepressants. Clin Pharmacokinet 2005;44:977–88.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Vitton O,
    2. Gendreau M,
    3. Gendreau J,
    4. Kranzler J,
    5. Rao SG

    . A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 2004;19 Suppl 1S27–35.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Nagaoka S,
    2. Ohno M,
    3. Sekiguchi A

    . An open-label clinical trial of milnacipran in fibromyalgia syndrome with co-morbid depressive symptoms. Int J Psychiatry Clin Pract 2004;8:47–51.

    OpenUrlCrossRef
29. 29.
    1. Kamata M,
    2. Takahashi H,
    3. Naito S,
    4. Higuchi H

    . Effectiveness of milnacipran for the treatment of chronic pain: a case series. Clin Neuropharmacol 2004;27:208–10.

    OpenUrlCrossRefPubMed
30. 30.
    1. Briley M

    . Clinical experience with dual action antidepressants in different chronic pain syndromes. Hum Psychopharmacol 2004;19 Suppl 1S21–5.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Kito S,
    2. Nakajima T,
    3. Koga Y

    . Milnacipran for the drastic improvement of refractory pain in a patient without depressive symptoms: a case report. Eur Psychiatry 2005;20:355.

    OpenUrlPubMed
32. 32.↵
    1. Sheehan DV,
    2. Lecrubier Y,
    3. Sheehan KH,
    4. et al

    . The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59 Suppl 2022–33.

    OpenUrlPubMed
33. 33.↵
    1. Ware JE,
    2. Kosinski M,
    3. Keller SK

    . SF-36 physical and mental health summary scales: a user’s manual. Boston: The Health Institute; 1994.
34. 34.↵
    1. Burckhardt CS,
    2. Clark SR,
    3. Bennett RM

    . The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 1991;18:728–33.

    OpenUrlPubMed
35. 35.
    1. Smets EM,
    2. Garssen B,
    3. Bonke B,
    4. De Haes JC

    . The Multidimensional Fatigue Inventory (MFI): psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315–25.

    OpenUrlCrossRefPubMed
36. 36.
    1. Beck AT,
    2. Ward CH,
    3. Mendelson M,
    4. Mock J,
    5. Erbaugh J

    . An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–71.

    OpenUrlCrossRefPubMed
37. 37.
    1. Hays RD

    . Sleep measures. Durham, NC: University Press; 1992.
38. 38.
    1. Hays RD,
    2. Martin SA,
    3. Sesti AM,
    4. Spritzer KL

    . Psychometric properties of the Medical Outcomes Study sleep measure. Sleep Med 2005;6:41–4.

    OpenUrlCrossRefPubMed
39. 39.
    1. Pincus T,
    2. Swearingen C,
    3. Wolfe F

    . Toward a multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum 1999;42:2220–30.

    OpenUrlCrossRefPubMed
40. 40.
    1. Seidenberg M,
    2. Haltiner A,
    3. Taylor MA,
    4. Hermann BB,
    5. Wyler A

    . Development and validation of a Multiple Ability Self-Report Questionnaire. J Clin Exp Neuropsychol 1994;16:93–104.

    OpenUrlPubMed
41. 41.↵
    1. McGahuey CA,
    2. Gelenberg AJ,
    3. Laukes CA,
    4. et al

    . The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26:25–40.

    OpenUrlCrossRefPubMed
42. 42.↵
    1. Farrar JT,
    2. Young JP, Jr,
    3. LaMoreaux L,
    4. Werth JL,
    5. Poole RM

    . Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149–58.

    OpenUrlCrossRefPubMed
43. 43.↵
    1. Dworkin RH,
    2. Turk DC,
    3. Wyrwich KW,
    4. et al

    . Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105–21.

    OpenUrlCrossRefPubMed
44. 44.↵
    1. Thumboo J,
    2. Fong KY,
    3. Chan SP,
    4. et al

    . A prospective study of factors affecting quality of life in systemic lupus erythematosus. J Rheumatol 2000;27:1414–20.

    OpenUrlPubMed
45. 45.
    1. Beaton DE,
    2. Boers M,
    3. Wells GA

    . Many faces of the minimal clinically important difference: a literature review and directions for future research. Curr Opin Rheumatol 2002;14:109–14.

    OpenUrlCrossRefPubMed
46. 46.
    1. Strand V,
    2. Scott DL,
    3. Emery P,
    4. et al

    . Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol 2005;32:590–601.

    OpenUrlAbstract/FREE Full Text
47. 47.
    1. Strand V

    . Longer term benefits of treating rheumatoid arthritis: assessment of radiographic damage and physical function in clinical trials. Clin Exp Rheumatol 2004;22:S57–64.

    OpenUrlPubMed
48. 48.
    1. Angst F,
    2. Aeschlimann A,
    3. Stucki G

    . Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Rheum 2001;45:384–91.

    OpenUrlCrossRefPubMed
49. 49.
    1. Strand V,
    2. Kelman A

    . Outcome measures in osteoarthritis: randomized controlled trials. Curr Rheumatol Rep 2004;6:20–30.

    OpenUrlPubMed
50. 50.↵
    1. Stucki G,
    2. Ewert T

    . How to assess the impact of arthritis on the individual patient: the WHO ICF. Ann Rheum Dis 2005;64:664–8.

    OpenUrlAbstract/FREE Full Text
51. 51.↵
    1. Mease P,
    2. Arnold LM,
    3. Bennett R,
    4. et al

    . Fibromyalgia syndrome. J Rheumatol 2007;34:1415–25.

    OpenUrlAbstract/FREE Full Text
52. 52.↵
    1. Arnold LM,
    2. Rosen A,
    3. Pritchett YL,
    4. et al

    . A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5–15.

    OpenUrlCrossRefPubMed
53. 53.↵
    1. Russell IJ,
    2. Mease PJ,
    3. Smith TR,
    4. et al

    . Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136:432–44.

    OpenUrlCrossRefPubMed
54. 54.↵
    1. Stahl SM,
    2. Grady MM,
    3. Moret C,
    4. Briley M

    . SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005;10:732–47.

    OpenUrlPubMed
55. 55.↵
    1. Epstein SA,
    2. Kay G,
    3. Clauw D,
    4. et al

    . Psychiatric disorders in patients with fibromyalgia. A multicenter investigation. Psychosomatics 1999;40:57–63.

    OpenUrlCrossRefPubMed
56. 56.↵
    1. Arnold LM,
    2. Russell IJ,
    3. Diri EW,
    4. et al

    . A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008;9:792–805.

    OpenUrlCrossRefPubMed
57. 57.↵
    1. Mease PJ,
    2. Russell IJ,
    3. Arnold LM,
    4. et al

    . A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008;35:502–14.

    OpenUrlAbstract/FREE Full Text
58. 58.↵
    1. Goldenberg D,
    2. Clauw DJ,
    3. Palmer RH,
    4. Gendreau RM

    . One-year durability of response to milnacipran treatment for fibromyalgia [abstract]. Arthritis Rheum 2007;56 SupplS603.

    OpenUrl